Search Results - research+area+%3e+cancer

13 Results Sort By:
Leukocyte-Derived Nanoparticles to Treat Triple-Negative Breast Cancer
This invention is an engineered biomimetic lipid-based nanoparticle (NP) functionalized with leukocyte membrane proteins (a.k.a. leukosomes) which are capable of targeting vascular inflammation. The ratio at which these leukocyte proteins are integrated within the NP shell dictates the biological behavior of the leukosomes. This particular formulation...
Published: 3/11/2021   |   Inventor(s): Francesca Taraballi, Assaf Zinger
Keywords(s):  
Category(s): Clinical Area > Cancer, Research Area > Cancer, Research Area > Nanomedicine, Technology Classifications > Therapeutic > Drug Delivery, Technology Classifications > Therapeutic > Nanovesicles
Beclin 2-Functionalized Therapies for Treatment of Neurodegenerative Disease and Cancer
This invention identified that Beclin 2 functions as a negative regulator of the ERK1/2 signaling, NF-κB signaling, and inflammasome activation. Furthermore, these studies demonstrated that Beclin 2 targets key signalling kinases for degradation through an ATG9A-dependent autophagic pathway. These new findings have uncovered an important role...
Published: 9/28/2020   |   Inventor(s): Rongfu Wang, Helen (Yicheng) Wang, Motao Zhu
Keywords(s):  
Category(s): Clinical Area > Cancer, Clinical Area > Neurology, Research Area > Cancer, Research Area > Immunobiology and Inflammation, Research Area > Neurology and Neurosurgery, Technology Classifications > Therapeutic > Biologics, Technology Classifications > Therapeutic > Small Molecules, Technology Classifications > Therapeutic > Immunotherapy
Specific PD-1 DNA Aptamers as Immunotherapeutic Agents in the Treatment of Cancers
The invention are therapeutic PD-1 DNA aptamers used to block PD-1 activity and enhance T-cell cytotoxicity against leukemias and solid tumors. Stage of Development In vitro data: Several aptamers were developed using SELEX technology against endogenous immunoprecipitated PD-1 and they were found to have highly conserved regions using high throughput...
Published: 8/31/2020   |   Inventor(s): Swaminathan Iyer, Santhana Thankgavelu Devaraj
Keywords(s):  
Category(s): Clinical Area > Cancer, Research Area > Cancer, Technology Classifications > Therapeutic > Immunotherapy
Ponatinib-Encapsulated Biomimetic Nanoparticle to Treat Osteosarcoma
This invention is a novel formulation of ponatinib which allows for targeted drug delivery to osteosarcoma tumors. This formulation utilizes a biomimetic lipid-based nanoparticle (NP) embedded with leukocyte membrane proteins (a.k.a. leukosomes). Previous iterations of leukosomes have demonstrated improved targeting of inflamed endothelium. Due to the...
Published: 7/23/2020   |   Inventor(s): Francesca Taraballi, Assaf Zinger, Ennio Tasciotti, Tomoyuki Naoi, Gherardo Baudo
Keywords(s):  
Category(s): Clinical Area > Cancer, Research Area > Cancer, Research Area > Nanomedicine, Technology Classifications > Therapeutic > Drug Delivery, Technology Classifications > Therapeutic > Nanovesicles, Technology Classifications > Therapeutic > Small Molecules
Microfibrillar-associated Protein 5 (MFAP5)-Specific Monoclonal Antibodies as Therapeutic Agents in Ovarian and Pancreatic Cancers
The invention are therapeutic monoclonal antibodies directed against microfibrillar-associated fibroblast-derived secreted protein 5 (MFAP-5) for the treatment of ovarian and pancreatic cancer. Cancer associated fibroblasts (CAFs) in the tumor stromal microenvironment exhibit altered secretion of extracellular proteins, which modify the tumor environment...
Published: 7/10/2020   |   Inventor(s): Stephen Wong, Jianting Sheng, Tsz Lun Yeung, Sze Lee Cecilia Leung, Samuel Mok
Keywords(s):  
Category(s): Clinical Area > Cancer, Research Area > Cancer, Technology Classifications > Therapeutic > Antibodies
Aptamer-engineered Natural Killer Cells for Adaptive Immunotherapy
The invention is a unique technology to engineer Natural Killer (NK) cells with synthetic oligonucleotide aptamers for tumor cell-specific cancer immunotherapy. Stage of Development In vitro Study: The aptamer-engineered NK (ApEn-NK) cells could be generated via a simple one-step process in minutes. The generated ApEn-NK cells were able to specifically...
Published: 7/10/2020   |   Inventor(s): Youli Zu
Keywords(s):  
Category(s): Clinical Area > Cancer, Research Area > Cancer, Clinical Area > Metabolic Disease, Inflammation, and Immunology, Technology Classifications > Therapeutic > Cell Therapy
Implantable therapeutic vaccine for the sustained long-term treatment and prevention of tumors and cancer (Nanolymph)
Description of InventionThe invention is a device consists of an immunostimulatory implant designed for the local recruitment and activation of immune cells against cancer. The system utilizes nanoporous membranes which allows for the sustained elution of immune adjuvants from transcutaneously refillable reservoirs embedded in the structure. With diffusion...
Published: 7/8/2020   |   Inventor(s): Alessandro Grattoni, Ying Chua
Keywords(s):  
Category(s): Clinical Area > Cancer, Research Area > Cancer, Technology Classifications > Medical Device > Implantables, Technology Classifications > Therapeutic > Cell and Gene Therapies
Chimeric antigen receptor modified immune cells recognizing DKK/HLA-A2 complex for cancer immunotherapy
The invention is a chimeric antigen receptor T cell therapy directed against solid tumors expressing the Dickkopf (Dkks) protein.. The Dickkopf family (Dkks) is a canonical Wnt signaling pathway antagonist which plays varied roles in human physiology and as well as assuming a central role in bone development and formation. As cancer cells, but not normal...
Published: 7/8/2020   |   Inventor(s): Qing Yi, Jianfei Qian, Wei Xiong
Keywords(s):  
Category(s): Clinical Area > Cancer, Research Area > Cancer, Technology Classifications > Therapeutic > Biologics
Monoclonal antibody recognizing DKK1/HLA-A2 complex for cancer immunotherapy
The invention is a monoclonal antibody directed against the Dickkopf (Dkks) protein. The Dkks family of proteins is a canonical Wnt signaling pathway antagonist which plays varied roles in human physiology and as well as assuming a central role in bone development and formation. As cancer cells, unlike normal cells, express on their surface DKKI peptides/HLA-A2...
Published: 7/8/2020   |   Inventor(s): Qing Yi, Jianfei Qian
Keywords(s):  
Category(s): Clinical Area > Cancer, Research Area > Cancer, Technology Classifications > Research Tool > Antibodies, Technology Classifications > Therapeutic > Biologics
IRF4-Targeted Therapies for Cancer, Transplant Rejection, and Autoimmune Disorders
This invention is a method of depleting or over-expressing the transcription factor, interferon regulatory factor 4 (IRF4), in T cells as therapeutic strategy for conditions which are highly regulated by the immune system. The inventors have established that IRF4 represses PD-1, Helios, and other molecules associated with T cell function, representing...
Published: 6/1/2020   |   Inventor(s): Wenhao Chen, Xian Li
Keywords(s):  
Category(s): Technology Classifications > Therapeutic > Cell and Gene Therapies, Clinical Area > Transplantation, Clinical Area > Cancer, Clinical Area > Metabolic Disease, Inflammation, and Immunology, Research Area > Cancer, Research Area > Immunobiology and Inflammation
1 2